Top Gold Stocks To Invest In Right Now


Related USO The Market In 5 Minutes: Black Friday Closes Shortened Trading Week The Market In 5 Minutes: Dow Hits 19,000 For First Time Ever Energy Recap: Another Move Up For The U.S. Oil Rig Count (Seeking Alpha) Related BNO Goldman Sachs Starts Imperial At Neutral, Positive On 'High-Quality Assets' And Fair Valuation Credit Suisse Upgrades Imperial Oil To Outperform, Says Recent Rebalance Favors Company Energy Recap: Another Move Up For The U.S. Oil Rig Count (Seeking Alpha)

Top Gold Stocks To Invest In Right Now: Nuveen Select Tax Free Income Portfolio(NXP)


Advisors’ Opinion:

  • [By Eric Volkman]

    Income investors might be wary of Qualcomm, as the company loves to spend its money — at times, its dividend payouts and share buybacks have exceeded free cash flow. Compounding that matter, the company should soon close the door on its acquisition of European peer NXP Semiconductor (NYSE:NXP), a deal with an estimated enterprise value of $47 billion.

Top Gold Stocks To Invest In Right Now: Teva Pharmaceutical Industries Limited(TEVA)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Teva Pharmaceutical Industries (TEVA) slashed its earnings guidance today and told investors that in 2017, it would be “focused on execution.” Of course, I’ve never heard a company tell investors that, hey, we’re not really going to focus on executing this year, but what do I know? I’m just a blogger. Maxim’s Gabrielle Zhou and team try to explain what Teva means:

    Getty Images


    Teva provided an updated business outlook for 2017. The company expects to continue its execution on the integration of the Actavis transaction. However, Teva reduced full year 2017 guidance…Net revenues are now estimated in a range of $23.8B-$24.5B, non-GAAP EPS is $4.90-$5.30 (based on weighted average shares of 1,076M). Recall that Teva provided a 2016-2019 preliminary financial outlook in July 2016 that included projected 2017 revenues of $25.2B-$26.2B and non-GAAP EPS of $6.00-$6.50; reduced guidance reflects delays in the timing of generic launches (some by a year), price erosion and external competition.


    Conclusion: we downgrade the stock to Hold from Buy. Teva is working to realize synergies from the Actavis business integration, launch new products in 2017, and generate free cash flow to the company, but challenges in the near term to the core generic and specialty business are becoming bigger issues. We will have to wait and see the company refocus on developing its organic growth. As such, we are downgrading the stock to Hold from Buy and lowering the price target to $41 from $49

    Shares of Teva Pharmaceutical Industries dropped 7.5% to $35.11 at 3:18 p.m. today.

  • [By Paul Ausick]

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) posted a new 52-week low of $31.90 on Wednesday, down about 0.7% compared with Tuesday’s closing price of $32.14. The stock’s 52-week high is $58.16. Volume was about 65% below the daily average of around 9.7 million shares. The company had no specific news.

  • [By Paul Ausick]

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) dropped about 6.6% Tuesday, to post a new 52-week low of $32.09 after closing at $34.35 on Monday. The stock’s 52-week high is $59.35. Volume was about 3 times the daily average of around 10 million shares. The company’s CEO left abruptly this morning.

  • [By Sean Williams]

    We’re in the thick of earnings season, which means some of the most prominent industry leaders are set to report their quarterly results. Tomorrow morning, Israel-based drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is set to join the crowd and release its first-quarter financial results.

  • [By Keith Speights]

    Teva Pharmaceutical Industries (NYSE:TEVA) hasn’t had much good news lately. Shares of the Israel-based drugmaker were hit hard in the second half of 2016.

Top Gold Stocks To Invest In Right Now: Attunity Ltd.(ATTU)


Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, ourUnder the Radar Moversnewsletter suggested small cap Big Data stock Attunity Ltd (NASDAQ: ATTU) as a short trade:

    “Attunity has also been on the watchlist for a while. It’s a straight-up momentum play Well, straight down momentum play. We’re just getting on board the train after a brief lull in the downtrend. This one isn’t going to be a monster-sized winner, but it’s a high-odds, low-risk trade.”

Top Gold Stocks To Invest In Right Now: CyberArk Software Ltd.(CYBR)

Advisors’ Opinion:

  • [By Joe Tenebruso]

    CyberArk Software (NASDAQ:CYBR) reported fourth-quarter financial results on Feb. 9. The Israeli cybersecurity specialist continues to win new business for its “privileged account” security solutions, which help to protect against cyberattacks that use insider privileges to penetrate network perimeters and assault the most sensitive areas of an enterprise’s IT infrastructure.

Leave a Reply

Your email address will not be published. Required fields are marked *